Abstract
The purpose of this study was to evaluate the presence of diffuse myocardial fibrosis in children and adolescents with hypertrophic cardiomyopathy (HCM) and to assess associations with echocardiographic and clinical parameters of disease. While a common end point in adults with HCM, it is unclear whether diffuse myocardial fibrosis occurs early in the disease. Cardiac magnetic resonance (CMR) estimation of myocardial post-contrast longitudinal relaxation time (T1) is an increasingly used method to estimate diffuse fibrosis. T1 measurements were taken using standard multi-breath-hold spoiled gradient echo phase-sensitive inversion-recovery CMR before and 15 min after the injection of gadolinium. The tissue–blood partition coefficient was calculated as a function of the ratio of T1 change of myocardium compared with blood. An echocardiogram and blood brain natriuretic peptide (BNP) levels were obtained on the day of the CMR. Twelve controls (mean age 12.8 years; 7 male) and 28 patients with HCM (mean age 12.8 years; 21 male) participated. The partition coefficient for both septal (0.27 ± 0.17 vs. 0.13 ± 0.09; p = 0.03) and lateral walls (0.22 ± 0.09 vs. 0.07 ± 0.10; p < 0.001) was increased in patients compared with controls. Eight patients had overt areas of late gadolinium enhancement (LGE). These patients did not show increased partition coefficient compared with those without LGE (0.27 ± 0.15 vs. 0.27 ± 0.19 and 0.22 ± 0.09 vs. 0.22 ± 0.09; p = 0.95 and 0.98, respectively). However, patients who were symptomatic (dyspnea, arrhythmia and/or chest pain) had higher lateral wall partition coefficient than asymptomatic HCM patients (0.27 ± 0.08 vs. 0.17 ± 0.08; p = 0.006). Similarly, patients with raised BNP (>100 pg/ml) had raised lateral wall coefficients (0.27 ± 0.07 vs. 0.20 ± 0.07; p = 0.03), as did those with traditional risk factors for sudden death (0.27 ± 0.06 vs. 0.18 ± 0.08; p = 0.007). Diffuse fibrosis, measured by the partition coefficient technique, is demonstrable in children and adolescents with HCM. Markers of fibrosis show an association with symptoms and raised serum BNP. Further study of the prognostic implication of this technique in young patients with HCM is warranted.
Similar content being viewed by others
Abbreviations
- HCM:
-
Hypertrophic cardiomyopathy
- CMR:
-
Cardiac magnetic resonance
- T1:
-
Longitudinal relaxation time
- BNP:
-
Brain natriuretic peptide
- LGE:
-
Late gadolinium enhancement
- LV:
-
Left ventricle
- E/A:
-
Mitral inflow early-to-late diastolic flow ratio
- IVRT:
-
Isovolumic relaxation time
- S/D:
-
Pulmonary venous systolic-to-diastolic peak velocity ratio
- E′lat:
-
Mitral lateral early diastolic tissue velocities
- E′med:
-
Septal peak early diastolic tissue velocities
- NYHA:
-
New York Heart Association
References
Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887. doi:10.1016/j.jacc.2010.05.007
Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ (2009) Normal right- and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 11:19. doi:10.1186/1532-429X-11-19
Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB (2013) Saturation recovery single-shot acquisition (SASHA) for myocardial T mapping. Magn Reson Med. doi:10.1002/mrm.24878
Dini FL, Michelassi C, Micheli G, Rovai D (2000) Prognostic value of pulmonary venous flow Doppler signal in left ventricular dysfunction: contribution of the difference in duration of pulmonary venous and mitral flow at atrial contraction. J Am Coll Cardiol 36(4):1295–1302
Dragulescu A, Mertens L, Friedberg MK (2013) Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: problems and limitations. Circ Cardiovasc Imaging 6(2):254–261. doi:10.1161/CIRCIMAGING.112.000175
Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM, Taylor AJ (2012) Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson 14:76. doi:10.1186/1532-429X-14-76
Flacke SJ, Fischer SE, Lorenz CH (2001) Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 218(3):703–710
Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122(2):138–144. doi:10.1161/CIRCULATIONAHA.109.930636
Geske JB, Sorajja P, Nishimura RA, Ommen SR (2007) Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 116(23):2702–2708. doi:10.1161/CIRCULATIONAHA.107.698985
Geske JB, McKie PM, Ommen SR, Sorajja P (2013) B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.04.004
Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 5(4):370–377. doi:10.1016/j.jcmg.2011.11.021
Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ (2008) Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52(19):1574–1580. doi:10.1016/j.jacc.2008.06.049
Kaski JP, Tome-Esteban MT, Mead-Regan S, Pantazis A, Marek J, Deanfield JE, McKenna WJ, Elliott PM (2008) B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart 94(10):1307–1311. doi:10.1136/hrt.2007.126748
Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, Iwase M, Murohara T, Yokota M (2004) Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 110(25):3808–3814. doi:10.1161/01.CIR.0000150334.69355.00
Liu CY, Liu YC, Wu C, Armstrong A, Volpe GJ, van der Geest RJ, Liu Y, Hundley WG, Gomes AS, Liu S, Nacif M, Bluemke DA, Lima JA (2013) Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 62(14):1280–1287. doi:10.1016/j.jacc.2013.05.078
Look DC, Locker DR (1970) Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 41:250–251
Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, Imaizumi T (1998) Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 82(6):774–778
Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109(8):984–989. doi:10.1161/01.CIR.0000117098.75727.D8
Nagakura T, Takeuchi M, Yoshitani H, Nakai H, Nishikage T, Kokumai M, Otani S, Yoshiyama M, Yoshikawa J (2007) Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy. Echocardiography 24(7):677–684. doi:10.1111/j.1540-8175.2007.00458.x
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22(2):107–133. doi:10.1016/j.echo.2008.11.023
Nishimura RA, Appleton CP, Redfield MM, Ilstrup DM, Holmes DR Jr, Tajik AJ (1996) Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 28(5):1226–1233. doi:10.1016/S0735-1097(96)00315-4
Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, Kinugasa Y, Tomikura Y, Igawa O, Hisatome I, Shigemasa C (2004) Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J 68(5):444–450
O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867–874. doi:10.1016/j.jacc.2010.05.010
Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, Maseri A, Frustaci A, Crea F (2007) Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Card Fail 13(5):380–388. doi:10.1016/j.cardfail.2007.01.011
Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, Pastor A, Carr-White G, Razavi R, Schaeffter T, Nagel E (2013) Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6(4):475–484. doi:10.1016/j.jcmg.2012.08.019
Raman FS, Kawel-Boehm N, Gai N, Freed M, Han J, Liu CY, Lima JA, Bluemke DA, Liu S (2013) Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners. J Cardiovasc Magn Reson 15:64. doi:10.1186/1532-429X-15-64
Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3(1):51–58. doi:10.1161/circheartfailure.109.854026
Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R, Lafitte S (2006) Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 47(6):1175–1181. doi:10.1016/j.jacc.2005.10.061
Sueyoshi E, Sakamoto I, Uetani M (2010) Contrast-enhanced myocardial inversion time at the null point for detection of left ventricular myocardial fibrosis in patients with dilated and hypertrophic cardiomyopathy: a pilot study. AJR Am J Roentgenol 194(4):W293–W298. doi:10.2214/AJR.09.3414
Tham EB, Haykowsky MJ, Chow K, Spavor M, Kaneko S, Khoo NS, Pagano JJ, Mackie AS, Thompson RB (2013) Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson 15(1):48. doi:10.1186/1532-429X-15-48
Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS, Ferranti J, Stainsby J, Liang B, Mazur W, Raman SV, Hor KN (2013) Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 6(6):873–880. doi:10.1161/CIRCIMAGING.113.000798
Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84(5):476–482
White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC (2013) T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 6(9):955–962. doi:10.1016/j.jcmg.2013.01.011
Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92(7):1680–1692
Acknowledgments
Andreas Greiser is an employee of Siemens Healthcare, Erlangen, Germany. All the other authors were not consultants or employees for Siemens Healthcare and had control of inclusion of any data and information that might present a conflict of interest for Andreas Greiser. We thank Judith Wilson and Sandra Aiello for their help with the data collection.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hussain, T., Dragulescu, A., Benson, L. et al. Quantification and Significance of Diffuse Myocardial Fibrosis and Diastolic Dysfunction in Childhood Hypertrophic Cardiomyopathy. Pediatr Cardiol 36, 970–978 (2015). https://doi.org/10.1007/s00246-015-1107-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-015-1107-7